MedTrace Logo

Nitroglycerin as Spasmolytic Regimen for RAS Prevention in Radial Center

NCT03889470 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2019-06-04

No results posted yet for this study

Summary

The investigators will investigate whether administration of Nitroglycerin (NTG) as spasmolytic regimen reduces the incidence of moderate to severe radial artery spasm (RAS) in patients undergoing transradial catheterization in radial center.

Conditions

  • Radial Artery Injury

Interventions

DRUG

NTG 1 MG/ML Injectable Solution

administered after sheath placement

Sponsors & Collaborators

  • Hermina Heart Center Kemayoran

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-31
Primary Completion
2019-09-30
Completion
2019-10-01

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03889470 on ClinicalTrials.gov